The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Samushiya M.A.

Central State Medical Academy of Department of Presidential Affairs

Al-Shukri A.S.

Academian I.P. Pavlov First Saint Petersburg State Medical University

Baranov I.I.

Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology

Ekusheva E.V.

Federal Research and Clinical Center of Specialized Types of Health Care and Medical Technology of the Federal Medical and Biological Agency

Livzan M.A.

Omsk State Medical University

Nenasheva N.M.

Russian Medical Academy of Continuous Professional Education

Tabeeva G.R.

Sechenov First Moscow State Medical University (Sechenov University)

Tamrazova O.B.

Peoples’ Friendship University of Russia

Tarasov A.V.

National Medical Research Center for Therapy and Preventive Medicine

Chernova A.A.

Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University;
Federal Siberian Research Clinical Center of the Federal Medical and Biological Agency

Development of a diagnostic and treatment algorithm for anxiety associated with somatic pathology in patients in general clinical practice. Resolution of the expert council

Authors:

Samushiya M.A., Al-Shukri A.S., Baranov I.I., Ekusheva E.V., Livzan M.A., Nenasheva N.M., Tabeeva G.R., Tamrazova O.B., Tarasov A.V., Chernova A.A.

More about the authors

Read: 1023 times


To cite this article:

Samushiya MA, Al-Shukri AS, Baranov II, et al. . Development of a diagnostic and treatment algorithm for anxiety associated with somatic pathology in patients in general clinical practice. Resolution of the expert council. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;125(1):62‑69. (In Russ.)
https://doi.org/10.17116/jnevro202512501162

Recommended articles:
Hysterical diso­rders in patients with hema­tological diseases. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(9):71-78
Effi­cacy of combined therapy of prurigo adultorum with application of temgicoluril anxiolytic. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(2):210-216

References:

  1. Kessler RC, Aguilar-Gaxiola S, Alonso J, et al. The global burden of mental disorders: an update from the WHO World Mental Health (WMH) surveys. Epidemiol Psichiatr Soc. 2009;18(1):23-33.  https://doi.org/10.1017/s1121189×00001421
  2. Smulevich AB, Drobizhev MYu, Ivanov SV. Clinical effects of benzodiazepine tranquilizers in psychiatry and general medicine. Moscow: Media Sphera Publ.; 2005. (In Russ.).
  3. Bosman RC, Ten Have M, de Graaf R, et al. Prevalence and course of subthreshold anxiety disorder in the general population: A three-year follow-up study. J Affect Disord. 2019;247:105-113.  https://doi.org/10.1016/j.jad.2019.01.018
  4. Smulevich AB, Drobizhev MYu, Ivanov SV. Benzodiazepine derivatives tranquilizers in psychiatry, psychosomatics and general medicine. Moscow: Media Sphera Publ.; 2005. (In Russ.).
  5. Deschênes SS, Burns RJ, Schmitz N. Anxiety and Depression Symptom Comorbidity and the Risk of Heart Disease: A Prospective Community-Based Cohort Study. Psychosom Med. 2020;82(3):296-304.  https://doi.org/10.1097/PSY.0000000000000790
  6. Shtarik S.Yu. The relationship between increased anxiety levels and arterial hypertension. Siberian Herald of Psychiatry and Narcology. 2010;2(59):69-73. (In Russ.).
  7. Player MS, Peterson LE. Anxiety disorders, hypertension, and cardiovascular risk: a review. Int J Psychiatry Med. 2011;41(4):365-377.  https://doi.org/10.2190/PM.41.4.f
  8. Smoller JW, Pollack MH, Wassertheil-Smoller S, et al. Panic attacks and risk of incident cardiovascular events among postmenopausal women in the Women’s Health Initiative Observational Study. Arch Gen Psychiatry. 2007;64(10):1153-1160. https://doi.org/10.1001/archpsyc.64.10.1153
  9. Tully PJ, Cosh SM, Baumeister H. The anxious heart in whose mind? A systematic review and meta-regression of factors associated with anxiety disorder diagnosis, treatment and morbidity risk in coronary heart disease. J Psychosom Res. 2014;77(6):439-448.  https://doi.org/10.1016/j.jpsychores.2014.10.001
  10. Gafarov VV, Gromova EA, Gagulin IV, et al. Gender peculiarities of the risk of cardiovascular diseases in a population with symptoms of depression in Siberia (the WHO MONICA-psychosocial program). Therapeutic Archive. 2017;89(9):60-67. (In Russ.). https://doi.org/10.17116/terarkh201789960-67
  11. Lomakin VV, Kopylov FY, Nikitina YM, et al. Psychosomatic features of atrial fibrillation. Russian Journal of Cardiology and Cardiovascular Surgery. 2009;2(1):61-65. (In Russ.).
  12. Chiu YC, Bai YM, Su TP, et al. Ischemic Stroke in Young Adults and Preexisting Psychiatric Disorders: A Nationwide Case-Control Study. Medicine (Baltimore). 2015;94(38):34-39.  https://doi.org/10.1097/MD.0000000000001520
  13. Eaker ED, Sullivan LM, Kelly-Hayes M, et al. Tension and anxiety and the prediction of the 10-year incidence of coronary heart disease, atrial fibrillation, and total mortality: the Framingham Offspring Study. Psychosom Med. 2005;67(5):692-696.  https://doi.org/10.1097/01.psy.0000174050.87193.96
  14. Tully PJ, Bennetts JS, Baker RA, et al. Anxiety, depression, and stress as risk factors for atrial fibrillation after cardiac surgery. J Acute Crit Care. 2011;40(1):4-11.  https://doi.org/10.1016/j.hrtlng.2009.12.010
  15. Lange HW, Herrmann-Lingen C. Depressive symptoms predict recurrence of atrial fibrillation after cardioversion. J Psychosomat Res. 2007;63(5):509-513.  https://doi.org/10.1016/j.jpsychores.2007.07.010
  16. Yu S, Zhao Q, Wu P, et al. Effect of anxiety and depression on the recurrence of paroxysmal atrial fibrillation after circumferential pulmonary vein ablation. J Cardiovasc Electrophysiol. 2012;23:17-23.  https://doi.org/10.1111/j.1540-8167.2011.02143.x
  17. Ferreira BR, Misery L. Psychopathology Associated with Chronic Pruritus: A Systematic Review. Acta Derm Venereol. 2023;103(6):34-39.  https://doi.org/10.2340/actadv.v103.8488
  18. Adesanya EI, Matthewman J, Schonmann Y, et al. Factors associated with depression, anxiety and severe mental illness among adults with atopic eczema or psoriasis: a systematic review and meta-analysis. Br J Dermatol. 2023;188(4):460-470.  https://doi.org/10.1093/bjd/ljac132
  19. Martin DA, Towne JE, Kricorian G, et al. The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings. J Invest Dermatol. 2013;133(1):17-26.  https://doi.org/10.1038/jid.2012.194
  20. Fabrazzo M, Cipolla S, Signoriello S, et al. A systematic review on shared biological mechanisms of depression and anxiety in comorbidity with psoriasis, atopic dermatitis, and hidradenitis suppurativa. Eur Psychiatry. 2021;64(1):e71.  https://doi.org/10.1192/j.eurpsy.2021.2249
  21. Fond G, Loundou A, Hamdani N, et al. Anxiety and depression comorbidities in irritable bowel syndrome (IBS): a systematic review and meta-analysis. Eur Arch Psychiatry Clin Neurosci. 2014;264(8):651-660.  https://doi.org/10.1007/s00406-014-0502-z
  22. Esterita T, Dewi S, Suryatenggara FG, Glenardi G. Association of Functional Dyspepsia with Depression and Anxiety: A Systematic Review. J Gastrointestin Liver Dis. 2021;30(2):259-266.  https://doi.org/10.15403/jgld-3325
  23. Zamani M, Alizadeh-Tabari S, Chan WW, Talley NJ. Association Between Anxiety/Depression and Gastroesophageal Reflux: A Systematic Review and Meta-Analysis. Am J Gastroenterol. 2023;118(12):2133-2143. https://doi.org/10.14309/ajg.0000000000002411
  24. Kim SY, Min C, Oh DJ, et al. Reciprocal association between depression and peptic ulcers: Two longitudinal follow-up studies using a national sample cohort. Sci Rep. 2020;10:1749. https://doi.org/10.1038/s41598-020-58783-0
  25. Hu S, Chen Y, Chen Y, Wang C. Depression and Anxiety Disorders in Patients With Inflammatory Bowel Disease. Front Psychiatry. 2021;12:714057. https://doi.org/10.3389/fpsyt.2021.714057
  26. Bailey JW, Cohen LS. Prevalence of mood and anxiety disorders in women who seek treatment for premenstrual syndrome. J Womens Health Gend Based Med. 1999;8(9):1181-1184. https://doi.org/10.1089/jwh.1.1999.8.1181
  27. Fazal TB, Razzaq Y, Ijaz F, et al. Comparison of Prevalence of Premenstrual Syndrome Symptoms among Medical and Non-medical Professional Females and its Association with Depression, Anxiety, and Stress: A Cross-sectional Study. Glob J Med Pharm Biomed Update. 2024;19:7.  https://doi.org/10.25259/GJMPBU_99_2023
  28. Abu Alwafa R, Badrasawi M, Haj Hamad R. Prevalence of premenstrual syndrome and its association with psychosocial and lifestyle variables: a cross-sectional study from Palestine. BMC Womens Health. 2021;21(1):233.  https://doi.org/10.1186/s12905-021-01374-6
  29. Huang S, Wang Z, Zheng D, Liu L. Anxiety disorder in menopausal women and the intervention efficacy of mindfulness-based stress reduction. Am J Transl Res. 2023;15(3):2016-2024.
  30. Li RX, Ma M, Xiao XR, et al. Perimenopausal syndrome and mood disorders in perimenopause: prevalence, severity, relationships, and risk factors. Medicine (Baltimore). 2016;95(32):e4466. https://doi.org/10.1097/MD.0000000000004466
  31. Mahjani B, Koskela LR, Batuure A, et al. Systematic review and meta-analysis identify significant relationships between clinical anxiety and lower urinary tract symptoms. Brain Behav. 2021;11(9):45-49.  https://doi.org/10.1002/brb3.2268
  32. Fava GA, Sonino N. Psychosomatic medicine: emerging trends and perspectives. Psychother Psychosom. 2000;69(4):184-97.  https://doi.org/10.1159/000012393
  33. Fava GA, Cosci F, Sonino N. Current Psychosomatic Practice. Psychother Psychosom. 2017;86(1):13-30.  https://doi.org/10.1159/000448856
  34. Mangelli L, Semprini F, Sirri L, et al. Use of the Diagnostic Criteria for Psychosomatic Research (DCPR) in a community sample. Psychosomatics. 2006;47(2):143-146.  https://doi.org/10.1176/appi.psy.47.2.143
  35. Shishkova VN. Anxiety disorders in patients with chronic somatic diseases: diagnostic and management algorithms in internist practice. Lechebnoe delo. 2024;2:36-44. (In Russ.). https://doi.org/10.24412/2071-5315-2024-13105
  36. Kroenke K, Spitzer RL, Williams JB, et al. Anxiety disorders in primary care: prevalence, impairment, comorbidity, and detection. Ann Intern Med. 2007;146(5):317-325.  https://doi.org/10.7326/0003-4819-146-5-200703060-00004
  37. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361-370.  https://doi.org/10.1111/j.1600-0447.1983.tb09716.x
  38. Volel BA, Petelin DS. Algorithms for diagnosis and therapy of mental disorders in general medical practice: a textbook. Moscow: MAI; 2020. (In Russ.).
  39. Gromov LI, Dudko EN. Typical and atypical tranquilizers. Vestnik farmakologii i farmatsii. 2003;(10):11-17. (In Russ.).
  40. Frolova NL, Chutko LS, Surushkina SYu. Psychovegetative features and therapeutic possibilities for patients with neurocirculatory asthenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2012;112(12):51-54. (In Russ.).
  41. Frolova NL, Chutko LS, Surushkina SYu. Psychovegetative disturbances in patients with stage I hypertension and possibilities of their correction. S.S. Korsakov Journal of Neurology and Psychiatry. 2013;113(9):43-47. (In Russ.).
  42. Shilina NN, Statcenko ME, Sporova OE, Lempert BA. Effectiveness of Adaptol and its differentiated use in patients with anxiety disorders during the post-infarction period. Therapeutic Archive. 2013;85(9):29-34. (In Russ.).
  43. Vorobyeva OV, Repina VV. Open comparative observational study of the efficacy and safety of Adaptol in the treatment of anxiety-asthenic disorders in patients with chronic cerebral ischemia. S.S. Korsakov Journal of Neurology and Psychiatry. 2016;116(3):45-49. (In Russ.). https://doi.org/10.17116/jnevro20161163120-24
  44. Mokina TV, Antipenko EA, Gustov AV. Use of adaptol in the treatment of chronic fatigue syndrome in patients with chronic cerebral ischemia. Neurosci Behav Physiol. 2010;40(7):757-759.  https://doi.org/10.1007/s11055-010-9322-4
  45. Zhivolupov SA, Samartsev IN, Marchenko AA, Pulyatkina OV. Prognostic significance of brain-derived neurotrophic factor (BDNF) levels during therapy of certain functional and organic nervous system diseases with adaptol. S.S. Korsakov Journal of Neurology and Psychiatry. 2012;112(4):37-41. (In Russ.).
  46. Kryzhanovsky SM, Samushiya MA, Iosava IK, Berestovoi MA. Effectiveness of Adaptol in the treatment of anxiety-depressive syndrome in patients with somatic pathology: a systematic analysis. Kremlevskaya meditsina. 2023;(1):43-50. (In Russ.).

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.